These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35614298)

  • 1. Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.
    Abegaz TM; Diaby V; Sherbeny F; Ali AA
    Clin Drug Investig; 2022 Jun; 42(6):501-511. PubMed ID: 35614298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
    Tisdale RL; Cusick MM; Aluri KZ; Handley TJ; Joyner AKC; Salomon JA; Chertow GM; Goldhaber-Fiebert JD; Owens DK
    J Gen Intern Med; 2022 Oct; 37(13):3380-3387. PubMed ID: 35137296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
    Bhatt AS; Vaduganathan M; Claggett BL; Kulac IJ; Anand IS; Desai AS; Fang JC; Hernandez AF; Jhund PS; Kosiborod MN; Sabatine MS; Shah SJ; Vardeny O; McMurray JJV; Solomon SD; Gaziano TA
    J Am Heart Assoc; 2024 Mar; 13(5):e032279. PubMed ID: 38390793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
    Bennett H; Tank A; Evans M; Bergenheim K; McEwan P
    Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
    Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
    JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
    Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective.
    Savira F; Wang BH; Kompa AR; Ademi Z; Owen AJ; Zoungas S; Tonkin A; Liew D; Zomer E
    Eur J Prev Cardiol; 2021 Aug; 28(9):975-982. PubMed ID: 34402872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt.
    Abdelhamid M; Elsisi GH; Seyam A; Shafie A; Kirollos M; Emad S; Mansy S; Sobhy M
    J Med Econ; 2022; 25(1):450-456. PubMed ID: 35291896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
    Huang K; Wang Y; Sun S; Zhu Q; Zhou W; Liu J; Zhu D; Xie X
    Front Public Health; 2022; 10():936703. PubMed ID: 35910934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.
    Vareesangthip K; Deerochanawong C; Thongsuk D; Pojchaijongdee N; Permsuwan U
    Adv Ther; 2022 Mar; 39(3):1279-1292. PubMed ID: 35038121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China.
    Yao Y; Zhang R; An T; Zhao X; Zhang J
    ESC Heart Fail; 2020 Dec; 7(6):3582-3592. PubMed ID: 33107212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.